Phase I Trial of a Malaria Vaccine Using Hepatitis B Core Particles
Author Information
Author(s): Gregson Aric L., Oliveira Giane, Othoro Caroline, Calvo-Calle J. Mauricio, Thorton George B., Nardin Elizabeth, Edelman Robert
Primary Institution: University of Maryland School of Medicine
Hypothesis
The study aims to assess the safety, reactogenicity, and immunogenicity of the ICC-1132 malaria vaccine adjuvanted with Alhydrogel.
Conclusion
The candidate malaria vaccine ICC-1132 was well tolerated but showed poor immunogenicity.
Supporting Evidence
- 95 to 100% of volunteers developed antibody responses to the ICC-1132 immunogen after two injections.
- Only 29-75% of volunteers developed malaria-specific responses.
- Local and systemic reactions were mild and well tolerated across dose cohorts.
Takeaway
Researchers tested a new malaria vaccine on healthy adults, and while it was safe, it didn't make people immune to malaria as well as hoped.
Methodology
This was a non-randomized, non-blinded, dose-escalating Phase I clinical trial assessing the vaccine's safety and immune response in healthy adults.
Potential Biases
The study was not blinded after the saline formulation was removed, which may introduce bias in reporting adverse events.
Limitations
The vaccine formulation was poorly immunogenic, and the malaria challenge trial was cancelled due to insufficient immunogenicity.
Participant Demographics
Participants were healthy, malaria-naive adults aged 18 to 45, with a median age of 25 years.
Statistical Information
P-Value
0.02
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website